Small Bone Innovations Introduces the Artelon(R) STT Spacer to Increase Treatment Options for Thumb Arthritis

U.S. Food and Drug Administration clears new implant for marketing

Sep 21, 2007, 01:00 ET from Small Bone Innovations, Inc.

    NEW YORK, Sept. 21 /PRNewswire/ -- Small Bone Innovations, Inc. (SBi),
 a single-source provider of products, technology and education for the
 small bone and joint sector of the orthopedic industry, announced that its
 Artelon(R) STT Spacer has been cleared by the FDA for marketing in the US.
     This product extends SBi's line of surgically implanted, degradable
 spacers to four applications with two others planned for future
 introduction. SBi introduced and began marketing this unique technology in
 the US in 2005 with the Arteon(R) CMC-I spacer for early to mid-stage
 osteo-arthritis (OA) in the base of the thumb.
     The Artelon STT Spacer is implanted in the scapho-trapezio-trapezoidial
 (STT) joint between the scaphoid and trapezial-trapezioid bones near the
 base of the thumb.
     *Dr. James Nunley, Chairman of the Orthopedics Department, Duke
 University, NC, said: "I am delighted to see FDA clearance of the Artelon
 STT spacer and, if it proves to be as good as the CMC-I spacer, it will be
 a tremendous benefit for patients likely to be presenting with a more
 advanced stage of OA in the base of the thumb."
     *Dr. Amit Gupta, Assistant Clinical Professor in the Department of
 Orthopedics at the University of Louisville, KY, added: "Artelon is a major
 advance in the treatment of small joint arthritis by providing an inert
 interpositioning material between joint surfaces that eventually degrades."
     The Artelon STT Spacer is similar in size to the Artelon CMC Spacer LG,
 except that it has a 'single-wing' design (an L-shape vs. a T-shape), of
 woven, degradable Artelon fibers. The spacer is designed to preserve the
 STT joint and to help restore joint function while minimizing the need to
 sacrifice healthy bone and tissue.
     Anthony G. Viscogliosi, Chairman & CEO of SBi, said: "The base of the
 thumb is one of the joints most commonly affected by osteoarthritis. The
 STT joint is usually affected at a later stage in the progression of the
 disease than is the more commonly diagnosed carpal-metacarpal (CMC-I)
     The addition of the Artelon STT Spacer expands SBi's coverage in the
 treatment algorithm and enables surgeons to offer a complementary range of
 spacers for every stage in the continuum of this debilitating disease.
     Mr. Viscogliosi noted that widespread use of hand-held devices is
 increasingly a cause of repetitive stress conditions in the thumb leading
 to earlier onset of arthritis and prompting more surgical procedures such
 as the use of Artelon spacers.
     "As with other Artelon spacers, of which more than 3,500 have been
 implanted since 2004, benefits may include restoring joint stability,
 faster recovery and post-operative elimination of pain," he added.
     Prior to the introduction of the Artelon Spacer, more aggressive
 procedures were and continue to be used as an initial surgical option.
 These procedures often involve removal of the trapezoidium bone and
 replacing it with tissue harvested from the forearm (known as an LRTI
 procedure) or complete fusion of the joint.
     SBi estimates that more than 40,000 of these procedures are performed
 on arthritic thumbs annually and that the number could rise to 55,000 by
     Mr. Viscogliosi added: "What these figures do not reflect is that many
 more patients elect not to seek surgery of any type and may rely on a
 combination of medication and bracing, but with Artelon technology now
 being offered by several hundred hand surgeons, these patients now have
 access to a much less aggressive form of treatment."
     Artelon Spacers now offer a new, less invasive, surgical option that
 spares healthy bone and tissue. The Artelon(R) CMC Spacer Arthro, cleared
 for marketing by the FDA earlier this year, permits minimally invasive
 arthroscopic implantation in patients at the earliest surgical stages of
 the condition.
     The Artelon STT Spacer introduction stems from SBi's world wide
 marketing and licensing agreements with Artimplant, AB, of Sweden. The
 Artelon STT Spacer and the recently introduced Artelon CMC Spacer Arthro,
 for minimally invasive surgery, are the latest in a line of six products
 either already in the market or under development. Two more spacer products
 are planned for future introduction in the US: the Artelon(R) MTP and
 Artelon(R) DRUJ have received European CE marks but are not yet cleared for
 sale in the US.
     For more details on Artelon products marketed by SBi visit:
     * Dr. Nunley has been compensated in the past by SBI for speaking
 engagements relating to medical education and marketing and may in the
 future be similarly compensated by SBI. Dr. Gupta is a counterparty to a
 product development/royalty agreement with SBI.
     About Small Bone Innovations, Inc.
     Small Bone Innovations, Inc. (SBi) was founded in 2004 by Viscogliosi
 Bros., LLC, (VB), the New York-based merchant banking firm that specializes
 in the musculoskeletal/orthopedic sector. VB created SBi as the first
 company to focus purely on small bone & joint science. By integrating
 established companies and professionals in the field, SBi can offer a
 broad, clinically proven portfolio of products and technologies to treat
 trauma and diseases in small bones & joints. Today, SBi has more than 130
 employees at facilities in New York, NY, Morrisville, PA and
 Bourg-en-Bresse, France.
     SBi closed on the sale of $42.2 million of its securities in December
 2005. At the time, based on data provided by Venture Source, this was the
 largest venture capital investment ever recorded in the field of orthopedic
     SBi was a 2006 recipient of Red Herring magazine's annual "Red Herring
 100 North America" award, recognizing SBi as one of the nation's leading
 technology companies and the only orthopedic device company selected among
 an initial entry of more than one thousand firms.
     Additionally, SBi's Artelon(R) CMC-I Spacer, developed for patients
 with osteoarthritis at the base of the thumb, was featured on the cover and
 highlighted within Medical Design Technology magazine's "Year of
 Innovation" issue as one of the most fascinating technologies influencing
 the medical device industry.
     Medical Device & Diagnostic Industry magazine named SBi to its list of
 "50 Companies to Watch" in 2006, noting, "Small Bone Innovations is going
 against the grain in its determination to become a market leader in the
 small bone & joint device sector."
     For more information on SBi, please visit:
     About Viscogliosi Bros., LLC
     Established by Marc R. Viscogliosi, John J. Viscogliosi and Anthony G.
 Viscogliosi in New York City in 1999, Viscogliosi Bros., LLC (VB) was the
 first venture capital/private equity and merchant banking firm dedicated to
 the musculoskeletal/orthopedics sector of the health care industry.
     Today, VB is a leading independent firm with a mission to create, build
 and finance companies founded on innovations developed by surgeons and
 uniquely focused on "life changing" musculoskeletal/orthopedic
 technologies. VB has worldwide surgeon, industry and trade relationships
 and significant financial expertise in the musculoskeletal/ orthopedic
     As principals of VB, the Viscogliosi brothers have a combined total of
 nearly half a century of experience analyzing and investing in the
 musculoskeletal/orthopedics sector, directing billions of dollars through
 the orthopedics industry. They have pioneered innovative financial,
 strategic and management initiatives for nearly 150 companies in the
 sector, from start-up, seed and development stage all the way to exit,
 while helping people lead better lives through the orthopedic and spinal
 products marketed and sold by the companies they have assisted in
 developing and financing.
     For more information about VB, please visit:
     About Artimplant AB
     Artimplant is a biomaterials company, based in Vastra Frolunda, Sweden,
 and focused on solutions to problems in orthopedic, odontological and
 reconstructive surgery. The Company is engaged in the development,
 production and marketing of degradable implants designed to restore active
 lifestyles and improve quality of life.
     The proprietary Artelon(R) technology, a long-term degradable
 biomaterial, offers new solutions to unmet clinical needs and opens new
 markets. Artimplant's business model is that of licensing its products and
 technology to global partners. The Company currently has six licensing
 agreements and one distribution agreement with three global partners.
 Artimplant is listed on the Stockholm Stock Exchange, O-list.
     Artelon(R) is a registered trademark of Artimplant AB.
     For additional information, please visit:
     Forward-looking statements
     This press release contains forward-looking statements as defined in
 the U.S. Private Securities Litigation Reform Act of 1995. Readers are
 cautioned not to place undue reliance on these forward-looking statements.
 Actual results may differ materially from those indicated by these
 forward-looking statements as a result of risks and uncertainties impacting
 SBi's business including increased competition; the ability of SBi to
 expand its operations and to attract and retain qualified professionals;
 technological obsolescence; general economic conditions; and other risks.

SOURCE Small Bone Innovations, Inc.